secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001528287-21-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q2 revenue $12.6M (+65% YoY); initial implants up 100%; reaffirms FY guidance
--------------------------------------------------------------------------------

- Total revenue $12.6M (+65% YoY); initial implant revenue $9.2M (+100% YoY, +14% QoQ).
- Net loss $8.5M vs $8.8M; cash $127.9M; long-term debt $49.4M.
- Reaffirmed FY2021 guidance: total revenue ~$47M, initial implant ~$36M.
- Received up to $9.3M NIH BRAIN grant to evaluate RNS System for Lennox-Gastaut Syndrome.
- Plans to start enrolling adolescent epilepsy patients before year-end; IDE for primary generalized epilepsy in 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828721000009/0001528287-21-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828721000009/npce-20210812.htm
  HTML page:      https://secwatch.observer/filing/0001528287-21-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer